ArticleAnnals of translational medicine2019

Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain.

Jose M Pacheco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.